Tradestie Institutional Equity Comparison Engine
INBX vs DMAC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DMAC Overall Edge
DMAC Captures Institutional Edge (3โ0 Pillars ยท 4โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, INBX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, INBX sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
INBX N/M vs DMAC N/M Fwd P/E
Growth & Margin Winner
DMAC
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner
DMAC
1Y +3.6% vs +55.3% ยท 52W Pos 20% vs 55%
Options & Structure Winner
DMAC
BREAKDOWN (8th %ile IV) vs SURGE (14th %ile IV)
INBX
NASDAQ
Inhibrx Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$77.32
-7.18% 1D
Market Cap
$1.3B
1M Return
-13.93%
1Y Return
+3.61%
Forward P/E
N/M
Unified AI Score
51.4 / 100
HOLD
Tech 48.0
Fund 55.0
Flow 68.0
Mom 50.0
DMAC
NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap
$503.1M
1M Return
+11.16%
1Y Return
+55.26%
Forward P/E
N/M
Unified AI Score
46.3 / 100
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
INBX +3.61%
DMAC +55.26%
Spread: +51.65 pp (DMAC Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | INBX Revenue | DMAC Revenue | INBX Op. Margin | DMAC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -1352.2% | DMAC |
| FY2023 | $0M | N/A | -12178.9% | N/A | INBX |
| FY2024 | $0M | N/A | -165724.0% | N/A | INBX |
| FY2025 | $0M | N/A | -10386.5% | N/A | INBX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | INBX | DMAC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.3B | $503.1M | Larger Scale | INBX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +0.0% | Higher Growth | DMAC |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -1773.6% | -114.6% | Higher ROE | DMAC |
| 52-Week Range Position Momentum | 20% ($57โ$155) | 55% ($5โ$11) | Stronger Trend | DMAC |
| Beta / 30D Volatility Risk Regime | 2.53ฮฒ ยท 120% Vol | 1.74ฮฒ ยท 98% Vol | Lower Realized Risk | DMAC |
| Unified Institutional Score Composite Signal | 51.4 / 100 (HOLD) | 46.3 / 100 (HOLD) | Higher Composite | INBX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full INBX vs DMAC Buy Guide
INBX
BREAKDOWN
134d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
DMAC
SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
14th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither INBX nor DMAC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.